(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/137274 A1

(51) International Patent Classification:
C07D 213/82 (2006.01) *A61P 35/00* (2006.01)
A61K 31/444 (2006.01)

(21) International Application Number:
PCT/US2011/034417

(22) International Filing Date:
29 April 2011 (29.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/329,710 30 April 2010 (30.04.2010) US

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BINDRA, Dilbir, S.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **GOKHALE, Madhushree Yeshwant** [IN/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **NUNES, Cletus John** [IN/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **ROSSO, Victor W.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **SCHROEDER, Gretchen, M.** [US/US]; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **THAKUR, Ajit, B.** [US/US]; 5 Disbrow Court, East Brunswick, New Jersey 08816 (US). **YIN, Xiaotian** [CA/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US).

(74) Agent: **GREENBLAT, Gary D.**; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/137274 A1

(54) **Title**: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4-ETHOXY-L-(4-FLUOROPHENYL)-2-OXO- 1,2-DIHYDROPYRIDINE-3 -CARBOXAMIDE

(57) **Abstract**: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4- yloxy)-3 -fluorophenyl)-4-ethoxy- 1 -(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3- carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4- yloxy)-3 -fluorophenyl)-4-ethoxy- 1 -(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3- carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino- 3 -chloropyridin-4-yloxy)-3 -fluorophenyl)-4-ethoxy- 1 -(4-fluorophenyl)-2-oxo- 1,2- dihydropyridine-3 -carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3- fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.